Plasma concentration is the amount of a substance—whether a medication, hormone, metabolite, or toxin—present in the liquid portion of blood at a specific moment. Because plasma is the transport medium that carries molecules throughout the body, its concentration serves as a practical window into drug exposure, biological activity, and potential toxicity. A single measurement, however, is rarely just a number; it is the visible result of absorption, distribution, metabolism, and excretion acting together.

Clinicians, pharmacists, and researchers rely on plasma concentration data to answer questions that dose alone cannot resolve. Why does one patient respond to a standard dose while another shows no effect or develops side effects? How quickly is a drug eliminated when kidney function declines? The answers often lie in how much drug is circulating in plasma, how much is free to act, and when the sample was collected.

What Plasma Concentration Really Measures
Plasma is obtained by centrifuging blood collected in a tube containing an anticoagulant. The resulting liquid contains water, electrolytes, proteins, hormones, and countless small molecules, but it excludes red blood cells, white blood cells, and platelets. When a laboratory reports a plasma concentration, it typically expresses the result as mass per volume, such as milligrams per liter or nanograms per milliliter, or as molarity.

That reported value reflects a dynamic balance rather than a permanent property of the patient. A drug can be absorbed from the gut, distributed into fat or muscle, bound to plasma proteins, metabolized by the liver, and excreted by the kidneys—all within hours. The plasma concentration at any given time is therefore a snapshot of those competing processes, and its meaning depends heavily on the dose, route, formulation, and sampling schedule.
Plasma vs. Serum and Whole Blood

Serum is the fluid that remains after blood clots, so it lacks fibrinogen and other clotting factors. Plasma is collected with an anticoagulant and retains those proteins. For many drugs, plasma and serum concentrations are close enough that reference ranges can be used interchangeably, but this is not universal. Some compounds bind to clotting factors or are affected by the anticoagulant itself, which can shift measured levels.
Whole blood includes the cellular components, and drugs that partition into red blood cells may show much higher whole blood concentrations than plasma concentrations. Immunosuppressants such as cyclosporine and tacrolimus are often monitored in whole blood because of this cellular distribution. The key practical point is consistency: a therapeutic threshold established for plasma should not be applied blindly to serum or whole blood results.
Total Versus Free Drug Concentration

Most drugs circulate partly bound to plasma proteins, especially albumin, alpha-1 acid glycoprotein, and lipoproteins. Only the unbound or free fraction can cross cell membranes and interact with receptors, enzymes, or ion channels. Routine assays frequently measure total plasma concentration, which includes both bound and free drug, even though the free fraction is often the pharmacologically active portion.
For highly protein-bound drugs, small changes in binding can produce large changes in free concentration without dramatically changing the total level. Phenytoin is a classic example: in patients with low albumin, the total plasma concentration may appear subtherapeutic while the free concentration is actually toxic. Free drug monitoring is therefore valuable in selected situations, including hypoalbuminemia, renal failure, liver disease, pregnancy, and suspected drug displacement interactions.
Clinical Applications of Plasma Concentration Monitoring

Therapeutic drug monitoring, often shortened to TDM, uses plasma concentration measurements to individualize medication dosing. It is most useful for drugs with a narrow therapeutic index, unpredictable pharmacokinetics, a clear relationship between concentration and response, and significant consequences of under- or over-dosing. Common candidates include vancomycin, aminoglycosides, digoxin, lithium, certain anticonvulsants, and immunosuppressants.
Interpretation requires more than comparing a result to a published range. The sample timing, steady-state status, dosage history, formulation, adherence, organ function, and concomitant medications all influence the number. A trough level drawn just before the next dose tells a different story from a peak level drawn shortly after infusion, and an area under the curve value may integrate exposure better than either one alone.








Therapeutic Drug Monitoring and Dosing
A well-run monitoring process begins with a defined target and a correctly timed sample. For vancomycin, many centers now use area under the curve guided dosing because it correlates better with efficacy and kidney safety than trough-only monitoring. For aminoglycosides, extended-interval regimens may use a single post-dose level to estimate clearance and adjust the next dose. For anticonvulsants, trough levels are often drawn before the morning dose once steady state has been reached.
Dose adjustments are grounded in pharmacokinetic principles. A loading dose is primarily determined by the volume of distribution, while a maintenance dose depends on clearance. If renal or hepatic function changes, clearance may fall, and plasma concentration can rise even when the dose has not changed. Bayesian dosing software, pharmacogenomic testing, and real-time clinical decision support are increasingly used to refine these estimates and reduce trial-and-error prescribing.
Factors That Change Plasma Concentration
Absorption can be altered by food, gastric pH, gastrointestinal motility, and formulation. Distribution can shift with body composition, protein binding, tissue perfusion, and barriers such as the blood-brain barrier. Metabolism depends on enzyme activity, genetic polymorphisms, liver function, and interactions with inhibitors or inducers. Excretion is influenced by kidney function, urine pH, and active transport systems in the renal tubules.
Patient-specific variables add another layer. Neonates and older adults often have different clearance and protein binding than healthy adults. Pregnancy increases blood volume and alters enzyme activity. Obesity changes volume of distribution for lipophilic drugs. Critical illness, sepsis, burns, and heart failure can unpredictably affect perfusion and organ function. Interactions such as grapefruit juice inhibiting CYP3A4, rifampin inducing enzymes, or ketoconazole blocking metabolism can push plasma concentrations into toxic or ineffective ranges.
Understanding plasma concentration is less about memorizing reference ranges and more about asking the right questions: What form of drug is being measured, when was the sample taken, what is the patient’s physiology doing, and what clinical outcome are we trying to achieve? As precision medicine grows, plasma concentration data will increasingly be combined with pharmacogenomics, biomarkers, and continuous monitoring to move dosing from population averages toward truly individualized care. Whether you are reviewing a laboratory result, designing a study, or adjusting a prescription, treating that number as part of a larger patient story will always lead to better decisions.